Hemostemix to Showcase Breakthrough Wound Healing Therapy at Innovations in Wound Care Conference Florida

Core Insights - Hemostemix Inc. is set to showcase its innovative angiogenic cell therapy, ACP-01, at the Innovations in Wound Care Conference, emphasizing its potential to improve circulation and heal wounds for patients with advanced conditions like Peripheral Arterial Disease and Critical Limb-Threatening Ischemia [1][3] Company Overview - Hemostemix operates in the regenerative medicine sector, focusing on autologous stem cell therapies, particularly the VesCell™ (ACP-01) treatment, which has shown significant clinical success in healing chronic wounds [7] - The company has completed multiple clinical studies, demonstrating the efficacy of ACP-01 in saving limbs from amputation and improving patient outcomes [2][5] Market Potential - The wound care market in Florida is estimated to be worth $500-$600 million, with a projected growth rate of 5-6% CAGR, expected to reach $700-$800 million in the next five years [3] - The global wound care market is anticipated to exceed $20 billion by 2030, driven by increasing rates of diabetes, vascular disease, and chronic wounds [4][6] Clinical Evidence - Clinical trials have shown that ACP-01 significantly reduces ulcer size, with treated patients experiencing a decrease from a mean of 146 mm² to 0.48 mm² within three months [5] - The treatment group in clinical studies reported a 0% mortality rate and a 4.8% amputation rate, compared to a 25% amputation rate in the placebo group [5] Strategic Positioning - Hemostemix is positioned as a first-mover in the regenerative medicine space for limb salvage, with ACP-01 already available under Florida SB-1768, addressing a significant unmet medical need [6]